Special: 5 Pro Tricks to Make Huge Returns in the Market



ICPT: Intercept Pharmaceuticals, Inc. is a Sell

The current rating for ICPT is 40, which is 25% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.